Literature DB >> 33628542

Henoch-Schönlein Purpura Associated with Lung Cancer: When Paraneoplastic Manifestations Impede Oncological Management.

Éloïse Philippe1,2, Aude Barnier2, Juliette Menguy2, Gilles Robinet1, Gilles Quéré1, Francis Couturaud2, Renaud Descourt1.   

Abstract

BACKGROUND: Henoch-Schönlein purpura (HSP) is an uncommon syndrome that mostly occurs in children, in whom it is frequently triggered by infections. In contrast, HSP in adults is more frequently of neoplastic origin. Case Presentation. We report HSP associated with a locally advanced lung squamous cell carcinoma that was considered a paraneoplastic syndrome. Systemic corticosteroids were given because a kidney biopsy revealed active glomerulonephritis. Concomitant chemoradiotherapy achieved a partial response of the lung tumor. Consolidation immunotherapy (programmed death protein-1-ligand-1 (PD-L1) inhibitor) was cancelled because HSP is known to be an autoimmune vasculitis, and long-term corticosteroid therapy was pursued.
CONCLUSION: Further prospective studies are needed to evaluate the effect of anti-PD-(L) 1 immunotherapies on autoimmune manifestations.
Copyright © 2021 Éloïse Philippe et al.

Entities:  

Year:  2021        PMID: 33628542      PMCID: PMC7884136          DOI: 10.1155/2021/8847017

Source DB:  PubMed          Journal:  Case Reports Immunol        ISSN: 2090-6617


  9 in total

1.  Henoch-Schönlein purpura as a clinical presentation of small cell lung cancer.

Authors:  R Blanco; M A González-Gay; D Ibáñez; C Alba; L A Pérez de Llano
Journal:  Clin Exp Rheumatol       Date:  1997 Sep-Oct       Impact factor: 4.473

2.  Henoch-Schönlein purpura associated with malignancy in adults.

Authors:  Joanna M Zurada; Kimberley M Ward; Marc E Grossman
Journal:  J Am Acad Dermatol       Date:  2006-08-28       Impact factor: 11.527

Review 3.  Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 2: Hematologic, cutaneous and vascular syndromes.

Authors:  Stéphane Holbrechts; Julie Gorham; Spyridon Sideris; Anne-Pascale Meert; Valérie Durieux; Thierry Berghmans; Jean-Paul Sculier
Journal:  Lung Cancer       Date:  2017-01-30       Impact factor: 5.705

4.  Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

Authors:  Kathryn C Arbour; Laura Mezquita; Niamh Long; Hira Rizvi; Edouard Auclin; Andy Ni; Gala Martínez-Bernal; Roberto Ferrara; W Victoria Lai; Lizza E L Hendriks; Joshua K Sabari; Caroline Caramella; Andrew J Plodkowski; Darragh Halpenny; Jamie E Chaft; David Planchard; Gregory J Riely; Benjamin Besse; Matthew D Hellmann
Journal:  J Clin Oncol       Date:  2018-08-20       Impact factor: 44.544

5.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

6.  Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.

Authors:  Alice Tison; Gilles Quéré; Laurent Misery; Elisa Funck-Brentano; François-Xavier Danlos; Emilie Routier; Caroline Robert; Yohann Loriot; Olivier Lambotte; Bertille Bonniaud; Camille Scalbert; Sarah Maanaoui; Thierry Lesimple; Stéphanie Martinez; Marie Marcq; Christos Chouaid; Catherine Dubos; Florence Brunet-Possenti; Chloé Stavris; Laurent Chiche; Nathalie Beneton; Sandrine Mansard; Florian Guisier; Hélène Doubre; François Skowron; François Aubin; Ouidad Zehou; Christophe Roge; Mickaël Lambert; Anne Pham-Ledard; Marie Beylot-Barry; Rémi Veillon; Nora Kramkimel; Damien Giacchero; Julie De Quatrebarbes; Catherine Michel; Jean-Bernard Auliac; Gilles Gonzales; Chantal Decroisette; Gwenaelle Le Garff; Ioana Carpiuc; Hervé Vallerand; Emmanuel Nowak; Divi Cornec; Marie Kostine
Journal:  Arthritis Rheumatol       Date:  2019-10-21       Impact factor: 10.995

7.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Corinne Faivre-Finn; Martin Reck; Johan Vansteenkiste; David R Spigel; Catherine Wadsworth; Giovanni Melillo; Maria Taboada; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

Review 8.  Vasculitis associated with malignancy. Experience with 13 patients and literature review.

Authors:  J M Greer; S Longley; N L Edwards; G J Elfenbein; R S Panush
Journal:  Medicine (Baltimore)       Date:  1988-07       Impact factor: 1.889

9.  Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Authors:  Leora Horn; David R Spigel; Everett E Vokes; Esther Holgado; Neal Ready; Martin Steins; Elena Poddubskaya; Hossein Borghaei; Enriqueta Felip; Luis Paz-Ares; Adam Pluzanski; Karen L Reckamp; Marco A Burgio; Martin Kohlhäeufl; David Waterhouse; Fabrice Barlesi; Scott Antonia; Oscar Arrieta; Jérôme Fayette; Lucio Crinò; Naiyer Rizvi; Martin Reck; Matthew D Hellmann; William J Geese; Ang Li; Anne Blackwood-Chirchir; Diane Healey; Julie Brahmer; Wilfried E E Eberhardt
Journal:  J Clin Oncol       Date:  2017-10-12       Impact factor: 44.544

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.